Figure 2.

Sirpα^−/− mice display enhanced macrophage inflammatory responses in MLDS-induced type I diabetes. WT and Sirpα^−/− mice were administered STZ (25 mg/kg) for 5 consecutive days (marked by purple lines and arrows). Hyperglycemia was considered when serum glucose >200 mg/dl in two consecutive tests. A) Blood glucose level (left) and frequency of hyperglycemic mice (right). B) Immunofluorescent staining of pancreatic islets showing CD11b⁺ leukocyte infiltration (green) and β cell loss (determined by insulin labeling, red) in non-diabetic and diabetic WT and Sirpα^−/− mice on d20. C) Flow cytometry analysis of CD11b⁺ leukocytes and CD11b⁺CD86⁺ M1 macrophages recovered from pancreatic islets of diabetic WT and Sirpα^−/− mice. Data in each panel represent at least three independent experiments. **, P < 0.01. ***, P < 0.001.